Health In Tech, Inc. (HIT) stands at the forefront of the digital health revolution, delivering innovative technology solutions that significantly improve healthcare delivery and patient outcomes. By leveraging cutting-edge data analytics and proprietary software, HIT empowers healthcare providers and patients to make informed decisions that enhance operational efficiencies. With a robust focus on compliance and cybersecurity, the company is well-equipped to navigate the complexities of the evolving digital health landscape. As the market expands, HIT is strategically positioned for sustained growth, aiming to play a crucial role in the advancement of technology-driven healthcare solutions on a global scale.
| Revenue (TTM) | $34.08M |
| Gross Profit (TTM) | $20.09M |
| EBITDA | $2.43M |
| Operating Margin | -24.60% |
| Return on Equity | -4.52% |
| Return on Assets | -2.76% |
| Revenue/Share (TTM) | $0.60 |
| Book Value | $0.33 |
| Price-to-Book | 3.10 |
| Price-to-Sales (TTM) | 2.00 |
| EV/Revenue | 1.663 |
| EV/EBITDA | 278.56 |
| Quarterly Earnings Growth (YoY) | 10.30% |
| Quarterly Revenue Growth (YoY) | 9.40% |
| Shares Outstanding | $53.86M |
| Float | $20.19M |
| % Insiders | 62.00% |
| % Institutions | 4.81% |
Volatility is currently contracting
STUART, Fla., June 29, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company") was added as a member of the Russell Microcap® Index, effective when the U.S. market opens on June 29, 2026, as part of the 2026 Russell U.S. indexes reconstitution.
Health In Tech, Inc. (HIT) Q1 2026 Earnings Call Transcript
Reiterates Guidance for 2026 Annual Revenue Ranging between $45 Million and $50 Million STUART, Fla., May 13, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three months ended March 31, 2026.
STUART, Fla., April 30, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it will release financial results for the first quarter ended March 31, 2026, following the close of market on Wednesday, May 13, 2026.
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy PONTE VEDRA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today announced a major regulatory milestone after successfully completing its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the Company's investigational first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT).
STUART, Fla., April 21, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) (the "Company"), an AI-enabled InsurTech platform company, today announced that it will be participating in the Market Movers Investor Summit on Tuesday, May 5, 2026.
Health In Tech, Inc. (HIT) Q4 2025 Earnings Call Transcript
STUART, Fla., March 25, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the "PIPE") that is expected to result in gross proceeds of approximately $7.0 million before deducting placement agent fees and offering expenses.
Full year 2025 Revenues of $33.3 million, up 71% YoY Full year 2025 Adjusted EBITDA of $4.1 million, up 81% YoY STUART, Fla., March 25, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
